Pilot 24 month study to compare mycophenolate mofetil and tacrolimus in the treatment of membranous lupus nephritis with nephrotic syndrome

Nephrology

Volumn 17, Issue 4, 2012, Pages 352-357

  Yap, Desmond Yh ^a   Yu, Xueqing ^b   Chen, Xiang Mei ^c   Lu, Fuming ^e   Chen, Nan ^f   Li, Xue Wang ^d   Tang, Colin So ^a   Chan, Tak Mao ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^c Department of Nephrology   (China)

^d PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^e FUDAN UNIVERSITY   (China)

^f SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

lupus; membranous; mycophenolate mofetil; nephritis; tacrolimus

Indexed keywords

CREATININE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; SERUM ALBUMIN; TACROLIMUS;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG BLOOD LEVEL; FEMALE; HERPES ZOSTER; HUMAN; INFECTION; LEUKOPENIA; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; MEMBRANOUS LUPUS NEPHRITIS; MULTICENTER STUDY; NEPHROTIC SYNDROME; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

ADULT; BIOLOGICAL MARKERS; BIOPSY; CHI-SQUARE DISTRIBUTION; CHINA; CREATININE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; NEPHROTIC SYNDROME; PILOT PROJECTS; PREDNISOLONE; PROSPECTIVE STUDIES; SERUM ALBUMIN; SEVERITY OF ILLNESS INDEX; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84860151628     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2012.01574.x     Document Type: Article

References (30)

1. Donadio JV Jr, Burgess JH, Holley KE,. Membranous lupus nephropathy: A clinicopathologic study. Medicine (Baltimore) 1977; 56: 527-36. (Pubitemid 8229841)
2. Bakir AA, Levy PS, Dunea G,. The prognosis of lupus nephritis in African-Americans: A retrospective analysis. Am. J. Kidney Dis. 1994; 24: 159-71. (Pubitemid 24249053)
3. Pasquali S, Banfi G, Zuchchelli A, Moroni G, Ponticelli C, Zuchchelli P,. Lupus membranous nephropathy: Long-term outcome. Clin. Nephrol. 1993; 39: 175-82. (Pubitemid 23112538)
4. Sloan RP, Schwartz MM, Korbet SM, Borok RZ,. Long-term outcome in systemic lupus erythematosus membranous glomerulonephritis. Lupus Nephritis Collaborative Study Group. J. Am. Soc. Nephrol. 1996; 7: 299-305. (Pubitemid 26092479)
5. Donadio JV Jr,. Treatment of membranous nephropathy in systemic lupus erythematosus. Nephrol. Dial. Transplant. 1992; 7 (Suppl 1): 97-104. (Pubitemid 23016775)
6. Balow JE, Austin HA 3rd,. Therapy of membranous nephropathy in systemic lupus erythematosus. Semin. Nephrol. 2003; 23: 386-91. (Pubitemid 37022042)
7. Austin HA 3rd, Illei GG, Braun MJ, Balow JE,. Randomized, controlled trial of prednisolone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J. Am. Soc. Nephrol. 2009; 20: 901-11.
8. Chan TM, Li FK, Wong RW, Wong KL, Chan KW, Cheng IK,. Sequential therapy for diffuse proliferative and membranous lupus nephritis: Cyclophosphamide and prednisolone followed by azathioprine and prednisolone. Nephron 1995; 71: 321-7.
9. Chan TM, Li FK, Hao WK, et al,. Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppression. Lupus 1999; 8: 545-51. (Pubitemid 29452568)
10. Swan JT, Riche DM, Riche KD, Majithia V,. Systematic review and meta-analysis of immunosuppressant therapy of clinical trials in membranous lupus nephritis. J. Investig. Med. 2011; 59: 246-58.
11. Sun HO, Hu WX, Xie HL, et al,. Long-term outcome of Chinese patients with membranous lupus nephropathy. Lupus 2008; 17: 56-61. (Pubitemid 351487021)
12. Bartosik LP, Lajoie G, Sugar L, Cattran DC,. Predicting progression in IgA nephropathy. Am. J. Kidney Dis. 2001; 38: 728-35.
13. Honkanen E, Tornroth T, Gronhagen-Riska C, Sankila R,. Long term survival in idiopathic membranous glomerulonephritis: Can the course be clinically predicted? Clin. Nephrol. 1994; 41: 127-34. (Pubitemid 24085374)
14. Lionaki S, Derebail V, Hogan SL, et al,. Venous thromboembolism in patients with membranous nephropathy. Clin. J. Am. Soc. Nephrol. 2012; 7: 43-51.
15. Bello AK, Hemmelgarn B, Lloyd A, et al,. Associations among estimated glomerular filtration rate, proteinuria, and adverse cardiovascular outcomes. Clin. J. Am. Soc. Nephrol. 2011; 6: 1418-26.
16. Chan TM, Li FK, Tang CS, et al,. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N. Engl. J. Med. 2000; 343: 1156-62.
17. Chan TM, Tse KC, Tang CS, Mok MY, Li FK,; Hong Kong Nephrology Study Group. Long-term study of mycophenolate mofetil as both induction and maintenance treatment for diffuse proliferative lupus nephritis. J. Am. Soc. Nephrol. 2005; 16: 1076-84. (Pubitemid 41710318)
18. Ginzler EM, Dooley MA, Aranow C, et al,. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N. Engl. J. Med. 2005; 353: 2219-28. (Pubitemid 41697285)
19. Appel GB, Contreras G, Dooley MA, et al,. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J. Am. Soc. Nephrol. 2009; 20: 1103-12.
20. Spetie DN, Tang Y, Rovin BH, et al,. Mycophenolate therapy of SLE membranous nephropathy. Kidney Int. 2004; 66: 2411-15.
21. Kasitanon N, Petri M, Haas M, Magder LS, Fine DM,. Mycophenolate mofetil as the primary treatment of membranous lupus nephritis with and without concurrent proliferative disease: A retrospective study of 29 cases. Lupus 2008; 17: 40-45. (Pubitemid 351487018)
22. Radhakrishnan J, Moutzouris D, Ginzler EM, Solomons N, Siempos II, Appel GB,. Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int. 2010; 77: 152-60.
23. Szeto CC, Kwan BC, Lai FM, et al,. Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis. Rheumatology (Oxford) 2008; 47: 1678-81.
24. Tse KC, Lam MF, Tang SC, Tang CS, Chan TM,. A pilot study on tacrolimus treatment in membranous or quiescent lupus nephritis with proteinuria resistant to angiotensin inhibition or blockade. Lupus 2007; 16: 46-51. (Pubitemid 46178086)
25. Margreiter R,. European Tacrolimus vs Ciclosporin Microemulsion Renal Transplantation Study Group. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: A randomized multicentre study. Lancet 2002; 359: 741-6. (Pubitemid 34215073)
26. Vincenti F, Jensik SC, Filo RS, Miller J, Pirsch J,. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: Evidence for improved allograft survival at five years. Transplantation 2002; 73: 775-82. (Pubitemid 34260577)
27. Bensman A, Niaudet P,. Non-immunologic mechanisms of calcineurin inhibitors explain its anti-proteinuric effects in genetic glomerulopathies. Pediatr. Nephrol. 2010; 25: 1197-9.
28. Faul C, Donnelly M, Merscher-Gomez S, Chang YH, Franz S, Delfgaauw J,. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat. Med. 2008; 14: 931-8.
29. Nankivell BJ, Borrows RJ, Fung CL, O' Connell PJ, Allen RD, Chapman JR,. The natural history of chronic allograft nephropathy. N. Engl. J. Med. 2003; 349: 2326-33. (Pubitemid 37509740)
30. Nankivell BJ, Borrows RJ, Fung CL, O' Connell PJ, Chapman JR, Allen RD,. Calcineurin inhibitor toxicity: Longitudinal assessment by protocol histology. Transplantation 2004; 78: 557-65. (Pubitemid 39097102)